Spoken approach
say this aloud Free preview- Opening: Transplantation does not remove the cause, so the original disease can come back, and recurrence means the same lesion on the native and the graft biopsy. It affects up to 20% of grafts and is the third commonest cause of graft loss after the first year. I follow KDIGO 2020 candidate guideline section 9, with Comprehensive Clinical Nephrology chapter 113 for treatment.
- History: I confirm the native diagnosis from the biopsy, the speed to kidney failure, the age at onset and any previous graft lost to recurrence. Then I place the disease: high and early risk for primary FSGS, aHUS and primary hyperoxaluria; frequent but slow for IgAN, MN and C3G; low for lupus, ANCA vasculitis and anti-GBM.
- Labs: I send the disease-specific tests: genetic testing in a child or young adult with FSGS, anti-PLA2R in MN, complement genetics and anti-factor H in aHUS and C3G, an infection, autoimmune and paraprotein screen in IC-MPGN, the anti-GBM titre, and antiphospholipid antibodies in lupus.
+ 5 more steps of the spoken answer for subscribers